San Jose, CA – According to filings with the U.S. Securities and Exchange Commission, Resolve Biosciences is raising $71,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Jason Gammack played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Resolve Biosciences
Resolve Biosciences is applying the power of Molecular Cartography to enable scientists to gain new insights based on the highest-resolution view of single-cell spatial biology. The platform features the company’s proprietary, multiplexed, single-molecule detection technology, which offers full spatial context at subcellular resolution, all in a workflow that preserves the sample tissue. The platform offers unparalleled sensitivity and specificity that helps scientists detect individual transcripts and rare signals to interpret fundamental biology and rapidly advance the understanding of complex biological questions in critical fields such as oncology, neuroscience, and infectious disease. The technology has been under development since 2016 and is currently available through an oversubscribed early access program.

To learn more about Resolve Biosciences, visit http://www.resolvebiosciences.com/

Contact:
Jason Gammack, Chief Executive Officer
408-944-5998

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved